Calcium and Vitamin D in Sarcoidosis: How to Assess and Manage

Robert R Burke; Benjamin A Rybicki; D. Sudhaker Rao

doi:10.1055/s-0030-1262215

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2010; 31(4): 474-484
DOI: 10.1055/s-0030-1262215

Calcium and Vitamin D in Sarcoidosis: How to Assess and Manage

Robert R. Burke¹ ^, ² , Benjamin A. Rybicki³ , D. Sudhaker Rao⁴

¹Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan
²Division of Pulmonary and Critical Care Medicine, Henry Ford Health System, Detroit, Michigan
³Department of Research Epidemiology and Biostatistics, Henry Ford Hospital, Henry Ford Health System, Detroit, Michigan
⁴Division of Endocrinology, Diabetes, and Bone and Mineral Disorders, Henry Ford Health System, Detroit, Michigan

Abstract

ABSTRACT

The synthesis of vitamin D is altered by the granulomatous inflammation of sarcoidosis leading to increased production of 1, 25-dihydroxyvitamin D. Mounting evidence suggests that vitamin D is an immunomodulating hormone that inhibits both antigen presentation by cells of the innate immune system, and the cytokine release and proliferation of Th1 cells. These and other extraskeletal health benefits have led to an increase in vitamin D assessment and pharmacological supplementation in the general population. This review highlights the altered synthesis and general immunomodulating properties of vitamin D with a special emphasis on known interactions with sarcoidosis. In addition, the assessment of vitamin D nutritional status, its pharmacological supplementation, and the management of bone health in patients with sarcoidosis are reviewed.

KEYWORDS

Sarcoidosis - vitamin D - 1 - 25-dihydroxyvitamin D

Volltext

Referenzen

REFERENCES

1 Rao D S. Perspective on assessment of vitamin D nutrition. J Clin Densitom. 1999; 2 457-464
2 Looker A C, Dawson-Hughes B, Calvo M S, Gunter E W, Sahyoun N R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002; 30 771-777
3 Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis. 2005; 15(4 Suppl 5) S5–97-101
4 Norman A W, Bouillon R, Whiting S J, Vieth R, Lips P. 13th workshop consensus for vitamin D nutritional guidelines. J Steroid Biochem Mol Biol. 2007; 103 204-205
5 Jones G, Strugnell S A, DeLuca H F. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998; 78 1193-1231
6 Baughman R P, Teirstein A S, Judson M A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001; 164(10 Pt 1) 1885-1889
7 Meyrier A, Valeyre D, Bouillon R, Paillard F, Battesti J P, Georges R. Different mechanisms of hypercalciuria in sarcoidosis: correlations with disease extension and activity. Ann N Y Acad Sci. 1986; 465 575-586
8 Adams J S, Gacad M A, Anders A, Endres D B, Sharma O P. Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis. Sarcoidosis. 1986; 3 1-6
9 DeLuca H F, Schnoes H K. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem. 1976; 45 631-666
10 Provvedini D M, Tsoukas C D, Deftos L J, Manolagas S C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983; 221 1181-1183
11 Bhalla A K, Amento E P, Clemens T L, Holick M F, Krane S M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983; 57 1308-1310
12 Veldman C M, Cantorna M T, DeLuca H F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000; 374 334-338
13 Niimi T, Tomita H, Sato S et al.. Vitamin D receptor gene polymorphism and calcium metabolism in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2000; 17 266-269
14 Niimi T, Tomita H, Sato S et al.. Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med. 1999; 160 1107-1109
15 Rybicki B A, Maliarik M J, Poisson L M, Iannuzzi M C. Sarcoidosis and granuloma genes: a family-based study in African-Americans. Eur Respir J. 2004; 24 251-257
16 Bellamy R, Ruwende C, Corrah T et al.. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis. 1999; 179 721-724
17 Roy S, Frodsham A, Saha B, Hazra S K, Mascie-Taylor C G, Hill A V. Association of vitamin D receptor genotype with leprosy type. J Infect Dis. 1999; 179 187-191
18 Wilkinson R J, Llewelyn M, Toossi Z et al.. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000; 355 618-621
19 Uitterlinden A G, Fang Y, Van Meurs J B, Pols H AP, Van Leeuwen J P. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004; 338 143-156
20 Reichel H, Koeffler H P, Tobler A, Norman A W. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A. 1987; 84 3385-3389
21 Gyetko M R, Hsu C H, Wilkinson C C, Patel S, Young E. Monocyte 1 alpha-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J Leukoc Biol. 1993; 54 17-22
22 Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006; 21 37-47
23 Rosenthal A M, Jones G, Kooh S W, Fraser D. 25-hydroxyvitamin D3 metabolism by isolated perfused rat kidney. Am J Physiol. 1980; 239 E12-E20
24 Overbergh L, Decallonne B, Valckx D et al.. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol. 2000; 120 139-146
25 Dusso A S, Kamimura S, Gallieni M et al.. Gamma-interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab. 1997; 82 2222-2232
26 Marshall T G. Vitamin D discovery outpaces FDA decision making. Bioessays. 2008; 30 173-182
27 Xu Y, Hashizume T, Shuhart M C et al.. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006; 69 56-65
28 Li T, Chen W, Chiang J Y. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007; 48 373-384
29 Zhou C, Assem M, Tay J C et al.. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest. 2006; 116 1703-1712
30 Blaney G P, Albert P J, Proal A D. Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann N Y Acad Sci. 2009; 1173 384-390
31 Merlino L A, Curtis J, Mikuls T R, Cerhan J R, Criswell L A, Saag K G. Iowa Women’s Health Study . Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum. 2004; 50 72-77
32 Costenbader K H, Feskanich D, Holmes M, Karlson E W, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis. 2008; 67 530-535
33 Hyppönen E, Läärä E, Reunanen A, Järvelin M R, Virtanen S M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001; 358 1500-1503
34 Lemire J M, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992; 12 143-148
35 Cantorna M T, Hayes C E, DeLuca H F. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr. 1998; 128 68-72
36 Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia. 1994; 37 552-558
37 Cantorna M T, Munsick C, Bemiss C, Mahon B D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000; 130 2648-2652
38 Clohisy D R, Bar-Shavit Z, Chappel J C, Teitelbaum S L. 1,25-Dihydroxyvitamin D3 modulates bone marrow macrophage precursor proliferation and differentiation: up-regulation of the mannose receptor. J Biol Chem. 1987; 262 15922-15929
39 Amento E P, Bhalla A K, Kurnick J T et al.. 1 alpha,25-dihydroxyvitamin D3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes, augments production of the monokine, mononuclear cell factor. J Clin Invest. 1984; 73 731-739
40 Zuckerman S H, Schreiber R D. Up-regulation of gamma interferon receptors on the human monocytic cell line U937 by 1,25-dihydroxyvitamin D3 and granulocyte-macrophage colony stimulating factor. J Leukoc Biol. 1988; 44 187-191
41 Liu P T, Stenger S, Li H et al.. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311 1770-1773
42 Ohta M, Okabe T, Ozawa K, Urabe A, Takaku F. In vitro formation of macrophage-epithelioid cells and multinucleated giant cells by 1 alpha,25-dihydroxyvitamin D3 from human circulating monocytes. Ann N Y Acad Sci. 1986; 465 211-220
43 Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000; 164 2405-2411
44 Piemonti L, Monti P, Sironi M et al.. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol. 2000; 164 4443-4451
45 Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli A M, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001; 167 1945-1953
46 Lemire J M, Adams J S, Kermani-Arab V, Bakke A C, Sakai R, Jordan S C. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol. 1985; 134 3032-3035
47 Provvedini D M, Manolagas S C. 1 Alpha,25-dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab. 1989; 68 774-779
48 Griffin M D, Lutz W H, Phan V A, Bachman L A, McKean D J, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000; 270 701-708
49 D’Ambrosio D, Cippitelli M, Cocciolo M G et al.. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998; 101 252-262
50 Matsui T, Takahashi R, Nakao Y et al.. 1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. Cancer Res. 1986; 46 5827-5831
51 Gorman S, Kuritzky L A, Judge M A et al.. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+ CD25+ cells in the draining lymph nodes. J Immunol. 2007; 179 6273-6283
52 Barrat F J, Cua D J, Boonstra A et al.. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002; 195 603-616
53 Hansdottir S, Monick M M, Hinde S L, Lovan N, Look D C, Hunninghake G W. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol. 2008; 181 7090-7099
54 Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros. 2007; 6 403-410
55 Morimoto T, Azuma A, Abe S et al.. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008; 31 372-379
56 Rossman M D, Thompson B, Frederick M ACCESS Group et al. HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008; 25 125-132
57 Mahévas M, Lescure F X, Boffa J J et al.. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore). 2009; 88 98-106
58 Adams J S, Sharma O P, Gacad M A, Singer F R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983; 72 1856-1860
59 Lafferty F W. Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991; 6(Suppl 2) S51-59 discussion S61
60 Ding E L, Mehta S, Fawzi W W, Giovannucci E L. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial. Int J Cancer. 2008; 122 1690-1694
61 Chlebowski R T, Johnson K C, Kooperberg C Women’s Health Initiative Investigators et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008; 100 1581-1591
62 LaCroix A Z, Kotchen J, Anderson G et al.. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women’s Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2009; 64 559-567
63 Lappe J M, Travers-Gustafson D, Davies K M, Recker R R, Heaney R P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007; 85 1586-1591
64 Wactawski-Wende J, Kotchen J M, Anderson G L Women’s Health Initiative Investigators et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006; 354 684-696
65 Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis. Sarcoidosis. 1991; 8 29-34
66 van Staa T P, Leufkens H G, Cooper C, Leufkens H GM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13 777-787
67 van Staa T P, Geusens P, Pols H AP, de Laet C, Leufkens H GM, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005; 98 191-198
68 Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis. 1988; 5 93-98
69 Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int. 1990; 5(3 Pt 1) 164-168
70 Heijckmann A C, Huijberts M S, De Vries J et al.. Bone turnover and hip bone mineral density in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007; 24 51-58
71 Rizzato G, Fraioli P. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility. Sarcoidosis. 1990; 7 89-92
72 Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis. 1988; 5 99-103
73 Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int. 1991; 49 71-76
74 Cummings S R, Karpf D B, Harris F et al.. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112 281-289
75 Karpf D B, Shapiro D R, Seeman E Alendronate Osteoporosis Treatment Study Groups et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA. 1997; 277 1159-1164
76 Gonnelli S, Rottoli P, Cepollaro C et al.. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997; 61 382-385
77 Qaseem A, Snow V, Shekelle P, Hopkins Jr R J, Forciea M A, Owens D K. Clinical Efficacy Assessment Subcommittee of the American College of Physicians . Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008; 149 404-415
78 American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis . Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001; 44 1496-1503
79 Bischoff-Ferrari H A, Willett W C, Wong J B, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293 2257-2264
80 Infante J R, Pacheco C, Torres-Avisbal M, Vallejo J A, González F M, Latre J M. Pulmonary activity in sarcoidosis: 67Ga uptake quantification and plasma determination of 1,25-dihydroxyvitamin D [in Spanish]. Rev Esp Med Nucl. 2002; 21 275-280
81 Kavathia D, Buckley J D, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010; 104 564-570
82 Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008; 177 330-336
83 Adams J S, Gacad M A, Diz M M, Nadler J L. A role for endogenous arachidonate metabolites in the regulated expression of the 25-hydroxyvitamin D-1-hydroxylation reaction in cultured alveolar macrophages from patients with sarcoidosis. J Clin Endocrinol Metab. 1990; 70 595-600
84 Reichel H, Koeffler H P, Barbers R, Norman A W. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab. 1987; 65 1201-1209
85 Rigby W F, Denome S, Fanger M W. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest. 1987; 79 1659-1664

Robert R BurkeM.D.

Division of Pulmonary and Critical Care Medicine

K17, Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202

eMail: Rburke1@hfhs.org